ClinicalTrials.gg
CompletedNCT01009047Updated Jun 21, 2013Results posted

An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia

A Phase 3 interventional study of Paliperidone extended release (ER) and Aripiprazole in Schizophrenia, sponsored by Janssen Research & Development, LLC. Completed at 44 sites in 7 countries. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2013-06-21.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 115 studies testing paliperidone in Schizophrenia — 6 open to participants now, 6 under way, none of them phase 3. paliperidone · Schizophrenia.

Enrollment
47th of 115
228 · median 178
Started
2009
with 10 others
Phase 3
41 of 115
none open now
Registered
50th of 115
by date
Lead sponsor
12 of 115
Janssen Research & Development, LLC

Among the 115 studies testing paliperidone in Schizophrenia, this one is the 47th largest by enrollment, is one of 11 that started in 2009, is one of 41 in phase 3, and was the 50th registered.

Schizophrenia

3,571 studies on the registry are indexed under Schizophrenia; 493 are open to participants now.

Browse Schizophrenia studies →

Open to participants now

6 of the 115 studies testing paliperidone in Schizophrenia are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About paliperidone

paliperidone: first FDA approval 2006 (INVEGA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 332 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (78%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies testing paliperidone in Schizophrenia, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the efficacy and safety of extended-release (ER) paliperidone compared to aripiprazole (atypical antipsychotic) in symptomatic (having symptoms) adolescent participants with schizophrenia (psychiatric disorder with symptoms of emotional instability, detachment from reality, often with delusions and hallucinations [imagining things], and withdrawal into the self) .

Read the detailed description

This is a multi-center (conducted in more than 1 center), double-blind (neither physician nor participant knows the name of the assigned drug), randomized (study drug is assigned by chance), active-controlled (paliperidone ER is compared to aripiprazole), parallel-group (a medical research study comparing the response in 2 or more groups of participants receiving different treatments), flexible-dose (the physician has the freedom to give different doses to the participant depending on how they respond to treatment) study designed to determine the efficacy and safety of paliperidone ER in symptomatic adolescents (12 to 17 years of age) with schizophrenia. The total duration of the study will be approximately 29 weeks. The study consists of 3 phases: a Screening phase up to 3 weeks (with a possible overlapping washout period), a Double-blind acute phase of 8 weeks, and a Double-blind maintenance phase of 18 weeks. Participants will be randomly assigned to 1 of the 2 treatment groups (paliperidone ER or aripiprazole flexible oral doses). Dosage will be adjusted at the scheduled visits. Efficacy of the participants will primarily be evaluated through Positive and Negative Syndromes Scale (PANSS). Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Schizophrenia

Browse trials for

Keywords

  • Schizophrenia
  • Paliperidone
  • Aripiprazole
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must currently meet the Fourth Edition (DSM-IV) criteria for schizophrenia and have experienced symptoms of the illness for at least 1 year, and they should have had at least treatment with 1 antipsychotic before participation in this study
  • Participants having a Positive and Negative Syndromes Scale (PANSS) score between 60 and 120 inclusive at Screening
  • Female participants must be incapable of pregnancy, or if heterosexually active and capable of pregnancy, have been using an acceptable method of for at least 1 month before study entry and agree to continue use contraception methods for the duration of the study, or if sexually abstinent (not having sexual intercourse) and capable of pregnancy, must agree to continue abstinence or to use an acceptable method of birth control
  • Participants must not be a danger to themselves or others, and must have family support available to be maintained as out-patients
  • Participants with a weight of equal to or greater than 29 kilogram

Exclusion criteria

Exclusion Criteria:

  • Participants with mild (not serious), moderate (medium level of seriousness), or severe (very serious, life threatening) mental retardation
  • Participants with a known or suspected history of substance dependence (including alcohol, but excluding nicotine or caffeine) as per the criteria in the 3 months before Screening
  • Participants with a history of certain neurological (pertaining to the nervous system) disorders or insulin-dependent diabetes mellitus (disorder in which there is decreased insulin in the body or the body's insulin is not effective, resulting in high blood sugar, increased thirst and urine, and many other side effects)
  • Participants who have received a depot injectable antipsychotic within 2 treatment cycles before the Screening visit
  • Participants who have received clozapine in 2 months before the Baseline visit (Day 1 of Week 1)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    Paliperidone extended-release (ER)

    Paliperidone ER will be administered as oral capsule at a dose of 6 milligram (mg) for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.

    Drug: Paliperidone extended release (ER)

  • Active comparator
    Aripiprazole

    Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.

    Drug: Aripiprazole

Interventions

  • Paliperidone ER will be administered as oral capsule at a dose of 6 mg for 1 week and then will be administered at a dose of either 3, 6 or 9 mg up to Week 26, once daily in the morning.

  • Aripiprazole will be administered as oral capsule at a dose of 2 mg on Days 1 and 2, 5 mg on Days 3 and 4, 10 mg Days 5, 6 and 7; and then will be administered as a dose of either 5 or 10 or 15 mg up to Week 26, once daily in the morning.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56

    The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline and Day 56

Secondary outcomes

  1. Change From Baseline in PANSS Total Score at Day 182

    The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

    Time frame: Baseline and Day 182

  2. Change From Baseline in Marder Factor Negative Symptoms Score at Day 56 and 182

    The PANSS negative subscale based on marder factor assesses 7 negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

    Time frame: Baseline, Day 56 and Day 182

  3. Change From Baseline in Other Marder Factors Scores at Day 56 and 182

    The subscales based on marder factors are: positive symptoms, disorganised thoughts factor, uncontrolled hostility/excitement factor, and anxiety/depression factor. The symptoms are rated on a 7-point scale, with a range of 8 to 56 for positive symptoms, 7 to 49 for disorganized thoughts and 4 to 28 for Uncontrolled hostility/excitement and anxiety/depression. Higher score indicate worsening.

    Time frame: Baseline, Day 56 and 182

  4. Change From Baseline in Other PANSS Factors and Subscales at Day 56 and 182

    The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).

    Time frame: Baseline, Day 56 and 182

  5. Number of Participants With Clinical Stability

    Clinical stability is defined as a decrease of 20 percent or more from Baseline in PANSS total score and CGI-S score less than or equal to 4 at Days 56 and 182, no hospitalizations due to psychiatric illness and no emergence of clinically significant suicidal or homicidal ideation during the maintenance phase.

    Time frame: Day 56 and 182

  6. Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Days 56 and 182

    The CGI-S rating scale is a 7-point global assessment that measures the Clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

    Time frame: Baseline, Day 56 and 182

  7. Change From Baseline in Personal and Social Performance (PSP) Scores at Day 56 and 182

    The PSP scale assesses degree of a participants' dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numerical score to rate degree of difficulty (1=absent to 6=very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score (total score ranges from 1 to 100, divided into 10 equal intervals). Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

    Time frame: Baseline, Day 56 and Day 182

  8. Number of Participants With PANSS Response

    The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Participants with PANSS response were defined as those who achieved greater than or equal to 20 percent or higher reduction from Baseline in the PANSS total score at Day 56 and 182.

    Time frame: Day 56 and 182

07

Results

Posted Jun 21, 2013

Participant flow

Participant flow — Overall Study
MilestonePaliperidone Extended Release (ER)Aripiprazole
Started113115
Completed8589
Not completed2826
Withdrew: Adverse event50
Withdrew: Lost to follow-up02
Withdrew: Lack of efficacy411
Withdrew: Withdrawal by consent1611
Withdrew: Other32

Outcome measures

PrimaryChange From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56

The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline and Day 56
Reported as:
Mean · Units on a scale
Change From Baseline in the Positive and Negative Syndrome Scale (PANSS) Total Score at Day 56
Units on a scalePaliperidone Extended Release (ER)Aripiprazole
Baseline89.6 ± 12.2292.0 ± 12.09
Change at Day 56-19.3 ± 13.80-19.8 ± 14.56
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.935 (Analysis of covariance (ANCOVA) model with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.) · Least-squares (ls) mean difference: 0.1 · 95% CI -3.46 to 3.76
SecondaryChange From Baseline in PANSS Total Score at Day 182

The PANSS is a 30-item scale designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The 30 symptoms are rated on a 7-point scale that ranges from 1 (absent) to 7 (extreme psychopathology). The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Higher scores indicate worsening.

Time frame:
Baseline and Day 182
Reported as:
Mean · Units on a scale
Change From Baseline in PANSS Total Score at Day 182
Units on a scalePaliperidone Extended Release (ER)Aripiprazole
Baseline89.6 ± 12.2292.0 ± 12.09
Change at Day 182-25.6 ± 16.88-26.8 ± 18.82
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.877 (Analysis of covariance (ANCOVA) model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.) · Ls mean difference: -0.3 · 95% CI -4.68 to 4.00
SecondaryChange From Baseline in Marder Factor Negative Symptoms Score at Day 56 and 182

The PANSS negative subscale based on marder factor assesses 7 negative-symptoms of schizophrenia. Negative symptoms represent a diminution or loss of normal functions. The symptoms are rated on a 7-point scale, with a range of 7 (absent) to 49 (extreme psychopathology).

Time frame:
Baseline, Day 56 and Day 182
Reported as:
Mean · Units on a scale
Change From Baseline in Marder Factor Negative Symptoms Score at Day 56 and 182
Units on a scalePaliperidone Extended Release (ER)Aripiprazole
Baseline23.2 ± 4.9223.3 ± 4.54
Change at Day 56-4.3 ± 4.56-4.7 ± 4.61
Change at Day 182-6.0 ± 5.51-6.2 ± 5.84
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.341 (Day 56: Analysis of covariance (ANCOVA) model with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.) · Ls mean difference: 0.5 · 95% CI -0.55 to 1.59
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.723 (Day 182: Analysis of covariance (ANCOVA) model with treatment (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.) · Ls mean difference: 0.2 · 95% CI -1.06 to 1.53
SecondaryChange From Baseline in Other Marder Factors Scores at Day 56 and 182

The subscales based on marder factors are: positive symptoms, disorganised thoughts factor, uncontrolled hostility/excitement factor, and anxiety/depression factor. The symptoms are rated on a 7-point scale, with a range of 8 to 56 for positive symptoms, 7 to 49 for disorganized thoughts and 4 to 28 for Uncontrolled hostility/excitement and anxiety/depression. Higher score indicate worsening.

Time frame:
Baseline, Day 56 and 182
Reported as:
Mean · Units on a scale
Change From Baseline in Other Marder Factors Scores at Day 56 and 182
Units on a scalePaliperidone Extended Release (ER)Aripiprazole
Baseline: Positive symptoms24.6 ± 4.0824.9 ± 4.32
Change at Day 56: Positive symptoms-6.1 ± 4.96-5.6 ± 4.83
Change at Day 182: Positive symptoms-7.8 ± 5.82-7.8 ± 6.03
Baseline: Negative symptoms23.2 ± 4.9223.3 ± 4.54
Change at Day 56: Negative symptoms-4.3 ± 4.56-4.7 ± 4.61
Change at Day 182: Negative symptoms-6.0 ± 5.51-6.2 ± 5.84
Baseline: Disorganized thoughts21.4 ± 4.4022.1 ± 3.86
Change at Day 56: Disorganized thoughts-4.0 ± 3.34-4.1 ± 3.40
Change at Day 182: Disorganized thoughts-5.5 ± 4.18-5.7 ± 4.46
Baseline: Uncontrolled hostility10.7 ± 3.1911.7 ± 3.48
Change at Day 56: Uncontrolled hostility-2.5 ± 2.67-2.9 ± 3.05
Change at Day 182: Uncontrolled hostility-3.2 ± 3.11-3.8 ± 3.97
Baseline: Anxiety/depression9.7 ± 3.1710.0 ± 3.26
Change at Day 56: Anxiety/depression-2.4 ± 3.08-2.6 ± 2.81
Change at Day 182: Anxiety/depression-3.0 ± 3.29-3.2 ± 3.17
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.351 (Change at Day 56: Positive Symptoms - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.691 (Change at Day 182:Positive Symptoms - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.965 (Change at Day 56: Disorganized thoughts - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.766 (Change at Day 182: Disorganized thoughts - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.984 (Change at Day 56: Uncontrolled hostility/ excitement - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.985 (Change at Day 182: Uncontrolled Hositility/ Excitement - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.803 (Change at Day 56: Anxiety/ depression - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.745 (Change at Day 182: Anxiety/ depression - ANCOVA model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate.)
SecondaryChange From Baseline in Other PANSS Factors and Subscales at Day 56 and 182

The PANSS provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items), each rated on a scale of 1 (absent) to 7 (extreme).

Time frame:
Baseline, Day 56 and 182
Reported as:
Mean · Units on a scale
Change From Baseline in Other PANSS Factors and Subscales at Day 56 and 182
Units on a scalePaliperidone Extended Release (ER)Aripiprazole
Baseline: Positive Subscale21.5 ± 4.1422.5 ± 4.26
Change at Day 56: Positive Subscale-6.4 ± 4.54-6.2 ± 4.91
Change at Day 182: Positive Subscale-8.0 ± 5.16-8.3 ± 6.09
Baseline: Negative Subscale23.8 ± 4.5524.2 ± 4.32
Change at Day 56: Negative Subscale-4.2 ± 4.254.5 ± 4.25
Change at Day 182: Negative Subscale-5.7 ± 5.15-6.1 ± 5.47
Baseline: General Psychopathology44.3 ± 7.4745.3 ± 7.01
Change at Day 56: General Psychopathology-8.7 ± 7.35-9.1 ± 7.25
Change at Day 182: General Psychopathology-11.9 ± 9.02-12.4 ± 9.41
SecondaryNumber of Participants With Clinical Stability

Clinical stability is defined as a decrease of 20 percent or more from Baseline in PANSS total score and CGI-S score less than or equal to 4 at Days 56 and 182, no hospitalizations due to psychiatric illness and no emergence of clinically significant suicidal or homicidal ideation during the maintenance phase.

Time frame:
Day 56 and 182
Reported as:
Number · Participants
Number of Participants With Clinical Stability
ParticipantsPaliperidone Extended Release (ER)Aripiprazole
Number of Participants With Clinical Stability5868
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · Cochran-Mantel-Haenszel · p = 0.296 (Generalized Cochran- Mantel- Haenszel test for row mean score differences controlling for country was used.)
SecondaryChange From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Days 56 and 182

The CGI-S rating scale is a 7-point global assessment that measures the Clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to "Normal, not at all ill" and a rating of 7 is equivalent to "Among the most extremely ill participants". Higher scores indicate worsening.

Time frame:
Baseline, Day 56 and 182
Reported as:
Median · Units on a scale
Change From Baseline in Clinical Global Impression - Severity (CGI-S) Score at Days 56 and 182
Units on a scalePaliperidone Extended Release (ER)Aripiprazole
Baseline4.0 (3 to 6)4.0 (3 to 6)
Change at Day 56-1.0 (-4 to 0)-1 (-3 to 1)
Change at Day 182-1.0 (-4 to 1)-1.0 (-4 to 1)
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.843 (Change at Day 56: ANCOVA model on ranks with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value (unranked) as a covariate was used.)
  • Paliperidone Extended Release (ER) · ANCOVA · p = 0.914 (Change at Day 182: ANCOVA model on ranks with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value (unranked) as a covariate was used.)
SecondaryChange From Baseline in Personal and Social Performance (PSP) Scores at Day 56 and 182

The PSP scale assesses degree of a participants' dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. The results of the assessment are converted to a numerical score to rate degree of difficulty (1=absent to 6=very severe) in each of the 4 domains. Based on 4 domains there will be 1 total score (total score ranges from 1 to 100, divided into 10 equal intervals). Participants with score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision.

Time frame:
Baseline, Day 56 and Day 182
Reported as:
Mean · Units on a Scale
Change From Baseline in Personal and Social Performance (PSP) Scores at Day 56 and 182
Units on a ScalePaliperidone Extended Release (ER)Aripiprazole
Baseline49.8 ± 10.3249.2 ± 10.21
Change at Day 5612.2 ± 11.7212.2 ± 10.17
Change at Day 18217.1 ± 14.4617.1 ± 14.03
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.895 (Change at Day 56: Analysis of covariance (ANCOVA) model with treatment groups(paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.) · Ls mean difference: 0.2 · 95% CI -2.34 to 2.67
  • Paliperidone Extended Release (ER) vs Aripiprazole · ANCOVA · p = 0.705 (Change at Day 182: Analysis of covariance (ANCOVA) model with treatment groups (paliperidone ER, aripiprazole) and country as factors, and baseline value as a covariate was used.) · Ls mean difference: 0.6 · 95% CI -2.64 to 3.89
SecondaryNumber of Participants With PANSS Response

The PANSS is a 30-item scale with each item rated on a scale of 1 (absent) to 7 (extreme psychopathology), designed to assess various symptoms of schizophrenia including delusions, grandiosity, blunted affect, poor attention, and poor impulse control. The PANSS total score consists of the sum of all 30 PANSS items and ranges from 30 to 210. Participants with PANSS response were defined as those who achieved greater than or equal to 20 percent or higher reduction from Baseline in the PANSS total score at Day 56 and 182.

Time frame:
Day 56 and 182
Reported as:
Number · Participants
Number of Participants With PANSS Response
ParticipantsPaliperidone Extended Release (ER)Aripiprazole
Day 567687
Day 1828693
Statistical analysis
  • Paliperidone Extended Release (ER) vs Aripiprazole · Cochran-Mantel-Haenszel · p = 0.119 (Day 56: Generalized Cochran-Mantel-Haenszel test for row mean score differences was used.)
  • Paliperidone Extended Release (ER) vs Aripiprazole · Cochran-Mantel-Haenszel · p = 0.444 (Day 182: Generalized Cochran-Mantel-Haenszel test for row mean score differences was used.)

Adverse events

Collected over Baseline up to Week 26. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Paliperidone Extended Release (ER)—7/113 (6.2%)63/113 (55.8%)
Aripiprazole—7/114 (6.1%)50/114 (43.9%)
Most frequent serious events
Most frequent serious events
EventPaliperidone Extended Release (ER)Aripiprazole
SchizophreniaPsychiatric disorders1/1134/114
AgitationPsychiatric disorders1/1131/114
AnxietyPsychiatric disorders1/1130/114
Schizophrenia, paranoid typePsychiatric disorders1/1130/114
Suicide attemptPsychiatric disorders1/1130/114
SinusitisInfections and infestations1/1130/114
Psychotic disorderPsychiatric disorders1/1131/114
Upper respiratory infectionInfections and infestations0/1131/114
Most frequent other events
Showing 10 of 13
Most frequent other events
EventPaliperidone Extended Release (ER)Aripiprazole
AkathisiaNervous system disorders13/1139/114
HeadacheNervous system disorders12/1135/114
SomnolenceNervous system disorders12/11312/114
TremorNervous system disorders12/11311/114
Weight increasedInvestigations12/1137/114
SchizophreniaPsychiatric disorders3/11310/114
InsomniaPsychiatric disorders6/1139/114
VomitingGastrointestinal disorders8/1131/114
Muscle rigidityMusculoskeletal and connective tissue disorders7/1133/114
NauseaGastrointestinal disorders4/1137/114

Baseline characteristics

Age Continuous
Age Continuous(Years)Paliperidone Extended Release (ER)AripiprazoleTotal
Mean15.3 ± 1.4615.4 ± 1.4515.3 ± 1.46
Sex: Female, Male
Sex: Female, Male(Participants)Paliperidone Extended Release (ER)AripiprazoleTotal
Female393877
Male7376149
08

Study locations

44 sites
  • Dothan, Alabama, United States
  • Santa Ana, California, United States
  • Atlanta, Georgia, United States
  • Smyrna, Georgia, United States
  • Lake Charles, Louisiana, United States
  • Shreveport, Louisiana, United States
  • Jaipur, India
  • Kanpur Uttarpradeh, India
  • Lucknow Gpo, India
  • Mangalore, India
  • Varanasi, India
  • Bucharest, Romania
  • Chelyabinsk, Russian Federation
  • Ekaterinburg Na, Russian Federation
  • Krasnodar N/A, Russian Federation
  • Moscow N/A, Russian Federation
  • Moscow Russia, Russian Federation
  • Nizhniy Novgorod, Russian Federation
  • Novosibirsk, Russian Federation
  • Saint Petersburg, Russian Federation
  • Samara, Russian Federation
  • Saratov, Russian Federation
  • Smolensk Region N/A, Russian Federation
  • St Petersburg, Russian Federation
  • St-Petersburg, Russian Federation
  • Tomsk Na, Russian Federation
  • Yaroslavl N/A, Russian Federation
  • Bratislava, Slovakia
  • Badajoz, Spain
  • Esplugues De Llobregat, Spain
  • Madrid, Spain
  • Paterna, Spain
  • Sabadell, Spain
  • Sevilla, Spain
  • Valladolid, Spain
  • Donetsk, Ukraine
  • Glevakha, Ukraine
  • Ivano-Frankivsk, Ukraine
  • Ivano-Frankovsk, Ukraine
  • Kharkiv, Ukraine
  • Kherson, Ukraine
  • Kiev, Ukraine
  • Poltava, Ukraine
  • Simferopol, Ukraine
09

References and documents

Publications

  • Savitz AJ, Lane R, Nuamah I, Gopal S, Hough D. Efficacy and safety of paliperidone extended release in adolescents with schizophrenia: a randomized, double-blind study. J Am Acad Child Adolesc Psychiatry. 2015 Feb;54(2):126-137.e1. doi: 10.1016/j.jaac.2014.11.009. Epub 2014 Nov 25. PubMed 25617253 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2009, a primary completion of Jun 2012 and a completion of Jun 2012. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2013, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 5, 2009
First posted
Nov 6, 2009
Start
Dec 2009
Primary completionActual
Jun 2012
CompletionActual
Jun 2012
Results first posted
Jun 21, 2013
Last update
Jun 21, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 21, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01009047
Responsible party
Sponsor
First posted
Nov 6, 2009
Start date
Dec 2009
Primary completion
Jun 2012
Completion
Jun 2012
Results posted
Jun 21, 2013
Last update
Jun 21, 2013

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Paliperidone

Start the discussion